Eudaven Ads
← Back to brand queue

Review · brand

David’s variant

David · 52 · Phoenix, AZ

Brief angle

“How to tell a serious compounded program from a warning-letter operator.”

Variant seed hook

“How to spot a compounded program that will still be operating in 2027.”

Meta IG Feed

Pharmacy-Transparent Plan

consideration

Versions — 1 total

v1

pending brand May 11, 00:12
Compliance 0.90 Brand 0.87

“How to spot a compounded program that will still be operating in 2027.”

Durable compounding operators share three characteristics: named 503A pharmacies, documented clinician evaluation for every patient, and third-party COA testing. Eudaven was built to that standard from day one — not retrofitted after a warning letter.

Read our pharmacy partner page

Decision history

When Role Decision Version Notes
May 13 22:20 clinician approve v1

Your decision · brand

Recording a decision against version v1 (current).

How to use

Review decision

Make your call on this variant. You're acting as brand — only your role's lens matters here.

What to check (by role)

  • Clinician: claims, efficacy language, contraindications, prescriber framing.
  • Brand: tone, persona fit, voice rules from data/kb/brand/sage-vitality.md.
  • Legal: GLP1-001..020 + FTC/FDA framing. Last chance to catch issues.

How to use this page

  1. Read the copy block(s) and any assets shown.
  2. Scan prior reviewer notes (if any) — context for what's already been raised.
  3. Pick a decision: Approve / Revise / Reject.
  4. If Revising, leave specific notes — they go straight into the regeneration prompt.
  5. If Approving as legal, this is terminal — the variant is shippable.

Tip

If you spot the same issue in multiple variants, mention it in your notes — that pattern can become a new entry in the regulatory KB so future briefs avoid it.